Sutro Biopharma Inc
STRO0.900USD
+0.175+24.17%
Fechamento 04/23, 16:00（ET）Cotações atrasadas em 15 min
74.27MValor de mercado
PerdaP/L TTM
Informações de Sutro Biopharma Inc Empresa
Sutro Biopharma, Inc. is a clinical-stage oncology company. The Company is engaged in developing site-specific and novel-format antibody drug conjugates (ADCs) enabled by its integrated cell-free protein synthesis platform, XpressCF, and its site-specific conjugation platform, XpressCF+. The Company’s advanced product candidate is STRO-002 (luveltamab tazevibulin, or luvelta), an ADC directed against folate receptor-alpha (FolRa), for patients with FolRa-expressing cancers, including ovarian cancer. In addition, it uses luvelta to treat pediatric patients with relapsed/refractory CBFA2T3-GLIS2 and acute myeloid leukemia. It also has two preclinical product candidates, STRO-003 and STRO-004. These product candidates are single homogeneous ADCs directed against an anti-receptor tyrosine kinase-like orphan receptor 1 (ROR1), and tissue factor (TF), each of which is being developed for the treatment of solid tumors.
Informações da empresa
Código da empresaSTRO
Nome da EmpresaSutro Biopharma Inc
Data de listagemSep 27, 2018
Fundado em2003
CEOMs. Jane Chung
Funcionários310
Tipo de TítulosOrdinary Share
Fim do ano fiscalSep 27
Endereço111 Oyster Point Blvd.
CidadeSOUTH SAN FRANCISCO
Bolsa de ValoresNASDAQ Global Market Consolidated
PaísUnited States of America
Código postal94080
Telefone16503928412
Sitehttps://www.sutrobio.com/
Código da empresaSTRO
Data de listagemSep 27, 2018
Fundado em2003
Executivos da Empresa
Nome
Nome/Posição
Posição
Ações Detidas
Variação
Ms. Jane Chung
Ms. Jane Chung
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
98.31K
+39.76%
Dr. Venkatesh Srinivasan, Ph.D.
Dr. Venkatesh Srinivasan, Ph.D.
Chief Technical Operations Officer
Chief Technical Operations Officer
52.08K
+35.51%
Mr. Daniel Hunter Petree
Mr. Daniel Hunter Petree
Independent Director
Independent Director
22.46K
+454.77%
Dr. Anne Borgman, M.D.
Dr. Anne Borgman, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Jon Marc Wigginton, M.D.
Dr. Jon Marc Wigginton, M.D.
Independent Director
Independent Director
--
--
Dr. Michael (Mike) Dybbs, Ph.D.
Dr. Michael (Mike) Dybbs, Ph.D.
Independent Director
Independent Director
--
--
Ms. Connie L. Matsui
Ms. Connie L. Matsui
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Ms. Sukhi Jagpal
Ms. Sukhi Jagpal
Director
Director
--
--
Mr. Joseph M. Lobacki
Mr. Joseph M. Lobacki
Independent Director
Independent Director
--
--
Mr. James P. (Jim) Panek
Mr. James P. (Jim) Panek
Independent Director
Independent Director
--
--
Ver Mais
Nome
Nome/Posição
Posição
Ações Detidas
Variação
Ms. Jane Chung
Ms. Jane Chung
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
98.31K
+39.76%
Dr. Venkatesh Srinivasan, Ph.D.
Dr. Venkatesh Srinivasan, Ph.D.
Chief Technical Operations Officer
Chief Technical Operations Officer
52.08K
+35.51%
Mr. Daniel Hunter Petree
Mr. Daniel Hunter Petree
Independent Director
Independent Director
22.46K
+454.77%
Dr. Anne Borgman, M.D.
Dr. Anne Borgman, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Jon Marc Wigginton, M.D.
Dr. Jon Marc Wigginton, M.D.
Independent Director
Independent Director
--
--
Dr. Michael (Mike) Dybbs, Ph.D.
Dr. Michael (Mike) Dybbs, Ph.D.
Independent Director
Independent Director
--
--
Detalhamento da Receita
Sem dados
Sem dados
Por Empresa
Por Região
Sem dados
Acionista
Tempo de atualização: dom, 6 de abr
Tempo de atualização: dom, 6 de abr
Estatísticas do Acionista
Tipo
Estatísticas do Acionista
Acionista
Proporção
Suvretta Capital Management, LLC
8.91%
BlackRock Institutional Trust Company, N.A.
7.51%
RA Capital Management, LP
5.29%
The Vanguard Group, Inc.
5.02%
Kynam Capital Management LP
4.35%
Other
68.92%
Estatísticas do Acionista
Acionista
Proporção
Suvretta Capital Management, LLC
8.91%
BlackRock Institutional Trust Company, N.A.
7.51%
RA Capital Management, LP
5.29%
The Vanguard Group, Inc.
5.02%
Kynam Capital Management LP
4.35%
Other
68.92%
Tipo
Acionista
Proporção
Hedge Fund
33.76%
Investment Advisor/Hedge Fund
24.76%
Investment Advisor
14.75%
Corporation
3.25%
Research Firm
3.03%
Venture Capital
2.86%
Individual Investor
1.15%
Pension Fund
0.46%
Bank and Trust
0.12%
Other
15.86%
Instituição Participações
Tempo de atualização: ter, 4 de mar
Tempo de atualização: ter, 4 de mar
Período do Relatório
Nº de instituições
Ações detidas
Proporção
Variação
2025Q1
282
70.21M
83.81%
-8.43M
2024Q4
299
65.68M
79.84%
-13.78M
2024Q3
295
64.44M
78.61%
-17.80M
2024Q2
286
64.98M
79.66%
-15.82M
2024Q1
291
55.64M
88.75%
-15.66M
2023Q4
302
58.38M
95.62%
-12.57M
2023Q3
306
61.36M
101.61%
-9.98M
2023Q2
312
60.26M
100.55%
-11.07M
2023Q1
320
58.55M
98.20%
-11.55M
2022Q4
332
54.70M
96.18%
-13.75M
Ver Mais
Atividade dos Acionistas
Nome
Ações detidas
Proporção
Variação
Chg %
Data
Suvretta Capital Management, LLC
7.46M
8.91%
+275.00K
+3.83%
Dec 31, 2024
BlackRock Institutional Trust Company, N.A.
6.29M
7.51%
+542.02K
+9.43%
Dec 31, 2024
RA Capital Management, LP
4.43M
5.29%
+4.43M
--
Mar 28, 2025
The Vanguard Group, Inc.
4.21M
5.02%
+13.43K
+0.32%
Dec 31, 2024
Kynam Capital Management LP
3.64M
4.35%
+1.57M
+76.22%
Dec 31, 2024
Merck & Co Inc
2.72M
3.25%
+2.72M
--
Dec 31, 2024
Vestal Point Capital, LP
2.57M
3.07%
+2.57M
--
Dec 31, 2024
Citadel Advisors LLC
2.46M
2.93%
+332.00K
+15.61%
Dec 31, 2024
Point72 Asset Management, L.P.
2.20M
2.62%
-799.91K
-26.69%
Dec 31, 2024
Samsara BioCapital, LLC
2.20M
2.62%
--
--
Dec 31, 2024
Ver Mais
ETFs Relacionados
Tempo de atualização: dom, 6 de abr
Tempo de atualização: dom, 6 de abr
Nome
Proporção
Range Cancer Immunotherapy ETF
0.76%
Invesco NASDAQ Future Gen 200 ETF
0.31%
ALPS Medical Breakthroughs ETF
0.11%
Avantis US Small Cap Equity ETF
0.01%
ProShares Ultra Nasdaq Biotechnology
0.01%
iShares Micro-Cap ETF
0.01%
Invesco Nasdaq Biotechnology ETF
0.01%
Fidelity Enhanced Small Cap ETF
0.01%
Global X Russell 2000 ETF
0%
iShares Russell 2000 ETF
0%
Ver Mais
Range Cancer Immunotherapy ETF
Proporção0.76%
Invesco NASDAQ Future Gen 200 ETF
Proporção0.31%
ALPS Medical Breakthroughs ETF
Proporção0.11%
Avantis US Small Cap Equity ETF
Proporção0.01%
ProShares Ultra Nasdaq Biotechnology
Proporção0.01%
iShares Micro-Cap ETF
Proporção0.01%
Invesco Nasdaq Biotechnology ETF
Proporção0.01%
Fidelity Enhanced Small Cap ETF
Proporção0.01%
Global X Russell 2000 ETF
Proporção0%
iShares Russell 2000 ETF
Proporção0%
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro das ações
Data de pagamento
Data de ex-dividendo
Sem dados
Desdobramento de Ações
Data
Tipo
Proporção
Sem dados
Data
Tipo
Proporção
Sem dados